Scientists from Russian biotechnology company “Biocad” have registered first domestic agent, containing recombinant human granulocyte colony-stimulating factor.
      
      Granulocyte colony-stimulating factor regulates formation of functionally active neutrophilic granulocytes (leucocytes, aimed at protecting organism from infections) and their delivery from bone marrow.
      
      Recombinant GCSF is often used in oncology, because chemotherapy is accompanied with neutrophil content drop. Moreover, GCSF is also used for activation of stem cell “emission” from bone marrow.
      
      Complex recombinant therapeutical agent, containing human GCSF gene, have passed all necessary clinical trials in leading Russian oncology clinics, which showed that domestic agent is sometimes even more effective than its foreign analogues and has less side effects.
      
      Source: Commercial Biotechnology